MBX - CIK 0001776111
The table below shows MBX Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $18.47M | $19.27M | $17.72M | $22.41M | $16.75M | $14.40M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.79M |
| $4.66M |
| $4.08M |
| $4.12M |
| $2.87M |
| $2.26M |
| Operating income | -$27.27M | -$23.93M | -$21.80M | -$26.53M | -$19.61M | -$16.66M |
| Income tax | - | - | - | - | - | - |
| Net income | -$23.52M | -$21.62M | -$19.41M | -$23.88M | -$18.14M | -$15.86M |
| EPS (diluted) | -$0.50 | -$0.63 | -$0.58 | -$0.71 | -$2.78 | -$12.62 |